Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	64343
Country	Italy

Category	Oncology
Manuscript Type	Minireviews
Article Title	Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Saleh A Alqahtani and Massimo G Colombo
Funding Agency and Grant Number
Corresponding Author	Massimo G Colombo, MD, Professor, Liver Center, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan 20132, Italy. mcolombo46@yahoo.it
Key Words	Hepatocellular carcinoma; Immune checkpoint inhibitor; Lenvatinib; Multi-tyrosine kinase inhibitor; Sorafenib
Core Tip	Recently, an immunotherapy-based combination of atezolizumab and bevacizumab was shown to prolong survival compared to sorafenib in unresectable hepatocellular carcinoma (HCC) patients who did not receive prior therapy. In addition, the combination of lenvatinib and pembrolizumab has yielded promising results in the same patient setting. This review article summarizes the results obtained with sorafenib and lenvatinib in patients with unresectable HCC in pivotal clinical trials and real-world studies. We offer guidance on the optimal choice between sorafenib or lenvatinib in an individual patient and discuss the immunotherapy-based combination, which will likely make the choice between sorafenib and lenvatinib somewhat obsolete.
Citation	Alqahtani SA, Colombo MG. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(12): 2038-2049

Received	2021-02-15 14:44
Peer-Review Started	2021-02-15 14:49
To Make the First Decision
Return for Revision	2021-03-15 04:54
Revised	2021-03-24 20:55
Second Decision	2021-10-15 06:33
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-10-15 09:02
Articles in Press	2021-10-15 09:02
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-09-29 19:20
Typeset the Manuscript	2021-12-07 04:32

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com